The FDA's adverse-event database FAERS now carries its first dedicated public dashboard for cosmetics — a Cosmetic Product module that segregates personal-care reports from drug, device and biologic cases. Dermatology Advisor outlines the launch in its walkthrough "A New Era of Cosmetics Safety: Examining the New FAERS Cosmetic Product Dashboard."

Why does a UI change matter for formulators?

Until now, cosmetic adverse-event reports lived inside the same data stream as drugs, devices and biologics. Searchers filtered pharmaceutical cases to surface reaction reports tied to a moisturizer, a cleanser or a color cosmetic. The new dashboard segregates cosmetic-product cases behind a dedicated interface.

The shift changes daily work for three professional groups:

• Formulators: ingredient-level reaction patterns become a public query, shortening the lead time on concentration decisions
• Compliance leads: case-intake phrasing turns into a permanent MedDRA-coded record on a public feed
• Clinicians: trend-checking across patch-test data and FAERS-coded reactions becomes a routine workflow

What does the module inherit from the rest of FAERS?

The cosmetic view plugs into the existing FAERS pipeline. That pipeline has tracked drug adverse events for decades through voluntary reports, manufacturer filings and international data-sharing feeds. Cosmetics were often filed into the same system informally; the new module makes that channel explicit and filterable.

Reactions are coded in MedDRA, the medical-terminology standard the FDA uses across every FAERS dashboard. Existing query habits therefore transfer without relearning — a deliberate design choice on the agency's part.

How does MoCRA shape the data flowing in?

The dashboard lands against the Modernization of Cosmetics Regulation Act of 2022. MoCRA expanded FDA authority over cosmetic safety, including serious adverse-event reporting obligations that apply to manufacturers on staged timelines.

For brands and contract manufacturers, two near-term consequences follow:

• Intake forms need higher internal QA — a reaction description written loosely at the consumer-call stage becomes a MedDRA-coded search field on the public dashboard
• A spike in reports on a given INCI across SKUs is now visible to competitors in near real time, sharpening competitive intelligence on every release

What limits does the dashboard carry?

FAERS remains a passive surveillance system. Consumer reporting is voluntary. Manufacturer reporting carries MoCRA's new mandates, but only for serious incidents and only on defined timelines. The standard FAERS caveats apply:

• Counts can rise as reporting improves, not because products degrade
• Absence of reports is not proof of safety
• MedDRA term groupings can mask ingredient-specific patterns

For dermatology clinics, the practical move is to cross-reference dashboard output with in-clinic patch-test data, treating neither as standalone.

Which products fall under the new module?

Under FDA definitions used elsewhere in MoCRA guidance, the dashboard pulls reports for personal-care items including skin care, hair care, color cosmetics, fragrances, oral care and certain baby-care items. Products regulated separately — drugs, sunscreens tested as OTC drugs, and color additives requiring premarket approval — typically populate other FAERS dashboards.

What should readers watch next?

Two milestones will define whether the dashboard matures into a working industry tool:

1. The first full annual cohort of MoCRA-mandated serious adverse-event filings — the baseline the module visualizes once volumes mature
2. Any FDA recalibration of MedDRA term groupings applied to cosmetic-class reactions

Until then, treat the new module as plumbing rather than verdict. The reporting baseline is still small, the medical coding is still being standardized, and the serious-event filing cadence is still ramping.